Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind vedolizumab IV maintenance therapy in pediatric ulcerative colitis
jRCT2071210030Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in autoimmune colitis (9 arms), sponsored by Takeda. Primary endpoint: Clinical remission at Week 54 based on modified Mayo score. Started Oct 2021; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2071210030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210030.